Drug intelligence / Profile preview

AG-702

Development stage: Discontinued
Lead developer: Agenus
Modality: Recombinant Proteins and Enzymes, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

AG-702 is a therapeutic vaccine developed as an immunostimulant, specifically designed to target herpes simplex virus type 2 (HSV-2). It consists of a noncovalent complex between an HLA A*0201-restricted epitope from the glycoprotein B protein of HSV-2 (gB2) and truncated human constitutive heat shock protein 70. The vaccine was intended to prime or boost CD8 T-cell responses in both HSV-naïve and HSV-2-infected individuals. Clinical studies demonstrated that AG-702 was safe and well tolerated, but it did not elicit new or boosted immune responses to the targeted HSV-2 epitope at the doses studied. Its development has been discontinued[1].

Targets

LRP1 (Prolow-density lipoprotein receptor-related protein 1)

Beyond the preview

Go deeper on AG-702.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG-702.

Explore the full profile